BR112015000585B1 - Métodos para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante de mhyo e seu uso, vacina e kit de vacinação - Google Patents

Métodos para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante de mhyo e seu uso, vacina e kit de vacinação Download PDF

Info

Publication number
BR112015000585B1
BR112015000585B1 BR112015000585-3A BR112015000585A BR112015000585B1 BR 112015000585 B1 BR112015000585 B1 BR 112015000585B1 BR 112015000585 A BR112015000585 A BR 112015000585A BR 112015000585 B1 BR112015000585 B1 BR 112015000585B1
Authority
BR
Brazil
Prior art keywords
mhyo
dna sequence
protein
gene
virus
Prior art date
Application number
BR112015000585-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015000585A2 (pt
BR112015000585A8 (pt
Inventor
Luis GONZALEZ GONZALEZ
Jaume PINOL RIBAS
Jordi MONTANE GIRALT
Maria CAMATS MALET
Enrique Querol Murillo
Marta SITJA ARNAU
Original Assignee
Hipra Scientific, S.L.U.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46832318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015000585(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hipra Scientific, S.L.U. filed Critical Hipra Scientific, S.L.U.
Priority to BR122022000531-4A priority Critical patent/BR122022000531B1/pt
Publication of BR112015000585A2 publication Critical patent/BR112015000585A2/pt
Publication of BR112015000585A8 publication Critical patent/BR112015000585A8/pt
Publication of BR112015000585B1 publication Critical patent/BR112015000585B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/70—Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
BR112015000585-3A 2012-07-10 2013-07-09 Métodos para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante de mhyo e seu uso, vacina e kit de vacinação BR112015000585B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122022000531-4A BR122022000531B1 (pt) 2012-07-10 2013-07-09 Cepa mutante de mhyo, vacina e kit de vacinação

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382277.7A EP2684959A1 (en) 2012-07-10 2012-07-10 Vectors for transforming Mycoplasma hyopneumoniae, transformed M.hyopneumoniae strains, and use thereof
EP12382277.7 2012-07-10
PCT/ES2013/070492 WO2014009586A2 (es) 2012-07-10 2013-07-09 Cepas mutantes de mycoplasma hyopneumoniae

Publications (3)

Publication Number Publication Date
BR112015000585A2 BR112015000585A2 (pt) 2017-08-08
BR112015000585A8 BR112015000585A8 (pt) 2018-01-16
BR112015000585B1 true BR112015000585B1 (pt) 2022-03-29

Family

ID=46832318

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122022000531-4A BR122022000531B1 (pt) 2012-07-10 2013-07-09 Cepa mutante de mhyo, vacina e kit de vacinação
BR112015000585-3A BR112015000585B1 (pt) 2012-07-10 2013-07-09 Métodos para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante de mhyo e seu uso, vacina e kit de vacinação

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122022000531-4A BR122022000531B1 (pt) 2012-07-10 2013-07-09 Cepa mutante de mhyo, vacina e kit de vacinação

Country Status (13)

Country Link
US (1) US10076561B2 (enExample)
EP (3) EP2684959A1 (enExample)
JP (2) JP6571523B2 (enExample)
KR (1) KR102157911B1 (enExample)
BR (2) BR122022000531B1 (enExample)
DK (2) DK2873733T4 (enExample)
ES (2) ES2745720T5 (enExample)
MX (1) MX362977B (enExample)
PL (1) PL2873733T5 (enExample)
PT (1) PT2873733T (enExample)
RU (1) RU2689671C2 (enExample)
WO (1) WO2014009586A2 (enExample)
ZA (1) ZA201500067B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2684959A1 (en) * 2012-07-10 2014-01-15 Laboratorios Hipra, S.A. Vectors for transforming Mycoplasma hyopneumoniae, transformed M.hyopneumoniae strains, and use thereof
WO2014174257A2 (en) * 2013-04-22 2014-10-30 The Royal Veterinary College Methods
EP2994162B1 (en) 2013-05-08 2021-04-07 Pharmgate Biologics Inc. Vaccine for pcv2 and mycoplasma
JP7510874B2 (ja) 2017-12-22 2024-07-04 ヒプラ シエンティフィック エセ．エレ．ウ． マイコプラズマ及びブタサーコウイルスに対する皮内混合ワクチン
CN110093324B (zh) * 2019-04-26 2020-02-18 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 基因缺失的减毒非洲猪瘟病毒及其作为疫苗的应用
RU2743595C1 (ru) * 2020-12-09 2021-02-20 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Вакцинная композиция против коронавирусной инфекции COVID-19
RU2743593C1 (ru) * 2020-12-09 2021-02-20 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Пептидные иммуногены и вакцинная композиция против коронавирусной инфекции COVID-19 с использованием пептидных иммуногенов
RU2743594C1 (ru) * 2020-12-09 2021-02-20 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Пептидные иммуногены, используемые в качестве компонентов вакцинной композиции против коронавирусной инфекции COVID-19
RU2752858C1 (ru) * 2021-02-04 2021-08-11 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Интегративный плазмидный вектор pVEAL2-S-RBD, обеспечивающий экспрессию и секрецию рекомбинантного рецепторсвязывающего домена (RBD) коронавируса SARS-CoV-2 в клетках млекопитающих, рекомбинантный штамм клеточной линии CHO-K1-RBD и рекомбинантный белок RBD SARS-CoV-2, продуцируемый указанным штаммом клеточной линии CHO-K1-RBD
WO2022186661A1 (ko) * 2021-03-04 2022-09-09 주식회사 이노백 돼지 마이코플라스마균 및 돼지 써코바이러스 감염 예방을 위한 다가 백신 조성물
KR102640730B1 (ko) * 2023-08-01 2024-02-29 주식회사 케어사이드 돼지 소모성 질병 관련 재조합 항원 제조용 신규한 벡터, 및 이를 이용한 백신 조성물
CN120366347A (zh) * 2025-03-17 2025-07-25 华南农业大学 一种质粒、副猪嗜血杆菌表面展示载体及其构建方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004295590B2 (en) * 2003-12-03 2010-04-29 Chugai Seiyaku Kabushiki Kaisha Expression systems using mammalian beta-actin promoter
AU2008324780A1 (en) * 2007-11-06 2009-05-14 Pah W Llc Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
KR20090061798A (ko) * 2007-12-12 2009-06-17 기아자동차주식회사 차량 시트용 시트 백의 허리 지지구조
TWI449533B (zh) * 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
JP2010136627A (ja) * 2008-12-09 2010-06-24 Nippon Oil Corp 酵母にガラクトースを利用させる方法
JP5257939B2 (ja) * 2009-02-24 2013-08-07 独立行政法人農業・食品産業技術総合研究機構 豚丹毒・豚マイコプラズマ肺炎経口投与型多価ワクチン
PE20120909A1 (es) * 2009-05-19 2012-08-19 Bioproperties Pty Ltd Cepa de vacuna de mycoplasma hyopneumoniae sensible a la temperatura y usos de la misma
CN102985530A (zh) * 2010-05-19 2013-03-20 澳大利亚生物资源公司 涉及减毒支原体的方法
EP2684959A1 (en) * 2012-07-10 2014-01-15 Laboratorios Hipra, S.A. Vectors for transforming Mycoplasma hyopneumoniae, transformed M.hyopneumoniae strains, and use thereof
WO2014174257A2 (en) 2013-04-22 2014-10-30 The Royal Veterinary College Methods

Also Published As

Publication number Publication date
ES3041296T3 (en) 2025-11-11
RU2689671C2 (ru) 2019-05-28
ES2745720T3 (es) 2020-03-03
EP2873733B1 (en) 2019-06-26
JP6883607B2 (ja) 2021-06-09
US10076561B2 (en) 2018-09-18
JP6571523B2 (ja) 2019-09-04
BR122022000531B1 (pt) 2022-06-21
US20150306200A1 (en) 2015-10-29
WO2014009586A2 (es) 2014-01-16
ZA201500067B (en) 2016-11-30
MX2015000287A (es) 2015-04-10
EP2873733A2 (en) 2015-05-20
JP2019176861A (ja) 2019-10-17
BR112015000585A2 (pt) 2017-08-08
RU2015104165A (ru) 2016-08-27
BR112015000585A8 (pt) 2018-01-16
PT2873733T (pt) 2019-10-14
MX362977B (es) 2019-02-28
EP3546580B1 (en) 2025-09-03
ES2745720T5 (es) 2023-06-05
JP2015523080A (ja) 2015-08-13
PL2873733T3 (pl) 2019-12-31
WO2014009586A3 (es) 2014-06-12
KR102157911B1 (ko) 2020-09-21
DK2873733T4 (da) 2023-04-03
WO2014009586A8 (es) 2019-02-21
PL2873733T5 (pl) 2023-05-15
KR20150027836A (ko) 2015-03-12
EP3546580A1 (en) 2019-10-02
EP2684959A1 (en) 2014-01-15
EP2873733B2 (en) 2023-01-18
DK2873733T3 (da) 2019-09-30
DK3546580T3 (da) 2025-12-01

Similar Documents

Publication Publication Date Title
JP6883607B2 (ja) マイコプラズマ・ハイオニューモニエを形質転換するためのベクター、形質転換されたマイコプラズマ・ハイオニューモニエの株、及びそれらの使用
JP7661552B2 (ja) ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法
Kwaga et al. A carAB mutant of avian pathogenic Escherichia coli serogroup O2 is attenuated and effective as a live oral vaccine against colibacillosis in turkeys
CN108064165A (zh) 猪流行性腹泻病毒株和由其产生的免疫原性组合物
US20080069843A1 (en) Salmonella vaccine
US20220273785A1 (en) Modified brucella vaccine strain for the treatment of brucellosis
CN105579060A (zh) Pcv2b趋异株疫苗组合物以及使用方法
US20080254062A1 (en) Use of an avirulent bordetella mutant as a live vaccine vector
CN104685057B (zh) 用于转化猪肺炎支原体的载体，转化的猪肺炎支原体菌株及其用途
KR20230141819A (ko) 약독화된 아프리카 돼지열병 바이러스 및 백신으로서의 이의 용도
WO2021125982A1 (es) Salmonella enteritidis recombinante y su uso como vacuna porcina
AU3935300A (en) Live attenuated bacteria for use in a vaccine
ES2524053T3 (es) Vacuna bacteriana contra agentes infecciosos bacterianos para la aplicación en animales
WO2025040802A1 (en) New scheme of administration of a multivalent vaccine against swine infections
JP2023543033A (ja) 弱毒化ブタ流行性下痢ウイルス

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/07/2013, OBSERVADAS AS CONDICOES LEGAIS.